630 related articles for article (PubMed ID: 29232923)
1. An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms.
Won E; Kim YK
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29232923
[TBL] [Abstract][Full Text] [Related]
2. Lithium, Stress, and Resilience in Bipolar Disorder: Deciphering this key homeostatic synaptic plasticity regulator.
Machado-Vieira R
J Affect Disord; 2018 Jun; 233():92-99. PubMed ID: 29310970
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge.
Ikonomov OC; Manji HK
Am J Psychiatry; 1999 Oct; 156(10):1506-14. PubMed ID: 10518159
[TBL] [Abstract][Full Text] [Related]
4. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness.
Manji HK; Moore GJ; Chen G
J Clin Psychiatry; 2000; 61 Suppl 9():82-96. PubMed ID: 10826666
[TBL] [Abstract][Full Text] [Related]
5. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.
Machado-Vieira R; Manji HK; Zarate CA
Bipolar Disord; 2009 Jun; 11 Suppl 2(Suppl 2):92-109. PubMed ID: 19538689
[TBL] [Abstract][Full Text] [Related]
6. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
[TBL] [Abstract][Full Text] [Related]
7. Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder.
Soeiro-de-Souza MG; Dias VV; Figueira ML; Forlenza OV; Gattaz WF; Zarate CA; Machado-Vieira R
Acta Psychiatr Scand; 2012 Nov; 126(5):332-41. PubMed ID: 22676371
[TBL] [Abstract][Full Text] [Related]
8. New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.
Bortolozzi A; Fico G; Berk M; Solmi M; Fornaro M; Quevedo J; Zarate CA; Kessing LV; Vieta E; Carvalho AF
Pharmacol Rev; 2024 May; 76(3):323-357. PubMed ID: 38697859
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding.
Malhi GS; Outhred T
CNS Drugs; 2016 Oct; 30(10):931-49. PubMed ID: 27638546
[TBL] [Abstract][Full Text] [Related]
10. Lithium as a Neuroprotective Agent for Bipolar Disorder: An Overview.
Ochoa ELM
Cell Mol Neurobiol; 2022 Jan; 42(1):85-97. PubMed ID: 34357564
[TBL] [Abstract][Full Text] [Related]
11. Glycogen synthase kinase 3beta as a likely target for the action of lithium on circadian clocks.
Padiath QS; Paranjpe D; Jain S; Sharma VK
Chronobiol Int; 2004 Jan; 21(1):43-55. PubMed ID: 15129823
[TBL] [Abstract][Full Text] [Related]
12. Lithium-associated transcriptional regulation of CRMP1 in patient-derived olfactory neurons and symptom changes in bipolar disorder.
McLean CK; Narayan S; Lin SY; Rai N; Chung Y; Hipolito MS; Cascella NG; Nurnberger JI; Ishizuka K; Sawa AS; Nwulia EA
Transl Psychiatry; 2018 Apr; 8(1):81. PubMed ID: 29666369
[TBL] [Abstract][Full Text] [Related]
13. Lithium-induced neuroprotective activity in neuronal and microglial cells: A purinergic perspective.
Gubert C; Andrejew R; Figueiro F; Bergamin L; Kapczinski F; Magalhães PVDS; Battastini AMO
Psychiatry Res; 2021 Jan; 295():113562. PubMed ID: 33213934
[TBL] [Abstract][Full Text] [Related]
14. Why is lithium effective in alleviating bipolar disorder?
Sato K
Med Hypotheses; 2021 Feb; 147():110484. PubMed ID: 33444905
[TBL] [Abstract][Full Text] [Related]
15. [A systematic analysis of neurobiological roles of lithium].
Gogoleva IV; Gromova OA; Torshin IY; Grishina TR; Pronin AV
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11):17-23. PubMed ID: 36440772
[TBL] [Abstract][Full Text] [Related]
16. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.
Chiu CT; Chuang DM
Pharmacol Ther; 2010 Nov; 128(2):281-304. PubMed ID: 20705090
[TBL] [Abstract][Full Text] [Related]
17. Lithium neuroprotection: molecular mechanisms and clinical implications.
Rowe MK; Chuang DM
Expert Rev Mol Med; 2004 Oct; 6(21):1-18. PubMed ID: 15488156
[TBL] [Abstract][Full Text] [Related]
18. Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder.
Benedetti F; Poletti S; Radaelli D; Locatelli C; Pirovano A; Lorenzi C; Vai B; Bollettini I; Falini A; Smeraldi E; Colombo C
Psychopharmacology (Berl); 2015 Apr; 232(7):1325-36. PubMed ID: 25345732
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder.
Munkholm K; Miskowiak KW; Jacoby AS; Vinberg M; Leme Talib L; Gattaz WF; Kessing LV
Eur Neuropsychopharmacol; 2018 Mar; 28(3):361-368. PubMed ID: 29433844
[TBL] [Abstract][Full Text] [Related]
20. Signal transduction pathways. Molecular targets for lithium's actions.
Manji HK; Potter WZ; Lenox RH
Arch Gen Psychiatry; 1995 Jul; 52(7):531-43. PubMed ID: 7598629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
